Tilly's (NYSE:TLYS) reported quarterly earnings of $0.66 per share which beat the analyst consensus estimate of $0.33 by 100 percent. This is a 842.86 percent increase over earnings of $0.07 per share from the same
--THE STUDY ESTABLISHES A NOVEL CONCEPT OF "TUMOR SUPPRESSIVE DRUG RESISTANCE"
--THE COMBINATION OF LB-100 WITH INHIBITORS OF CELLULAR STRESS RESPONSE MODULATORS WAS HIGHLY EFFECTIVE IN